OSIVAX
  • COMPANY
    • ABOUT US
    • EXECUTIVE COMMITTEE
    • SCIENTIFIC ADVISORY BOARD
    • CLINICAL ADVISORY BOARD
    • BOARD OF DIRECTORS
    • PARTNERS
  • SCIENCE
  • PIPELINE
    • OVERVIEW
    • INFLUENZA - OVX836
    • CORONAVIRUS
  • NEWS
    • PRESS RELEASES
    • MEDIA COVERAGE
    • PUBLICATIONS
    • EVENTS
  • CONTACT
    • CAREERS >
      • Analyste Business Development
      • Technicien R&D (H/F) Poste en CDD de 6 mois, basé à Lyon (69)
    • LEGAL MENTIONS

OVX836 - Universal Flu Vaccine Candidate

Osivax universal influenza vaccine candidate

overview
Influenza remains a devastating disease. 
Picture
Current seasonal vaccines triggering an antibody response against surface antigens (hemagglutinin and neuraminidase) are only partially effective, especially for patients over 65 years old : 25% effectiveness in the 2016-17 season in the US (3)
Picture

A paradigm shift is essential in influenza vaccination

Osivax is developing a game-changing universal influenza vaccine
  • Osivax’s vaccine targets the NucleoProtein (NP), a highly conserved internal antigen, much less prone to mutations than the traditional surface antigens targeted by current flu vaccines, thus alleviating the need for annual updates​
Picture
  • oligoDOM® technology enables the transformation of the NucleoProtein into a highly immunogenic antigen to trigger powerful B- and T-cells immune responses
Picture
Preclinical development on OVX836 universal flu vaccine candidate showed:
  • powerful systemic and local immune responses
  • strong efficacy in mice and ferrets challenge studies with multiple Flu viruses
  • an excellent safety profile in a GLP preclinical toxicology study

​OVX836 is a Phase IIa clinical trial, conducted by Dr Isabel Leroux-Roels in The Center for Vaccinology of the Ghent University (CEVAC).  
1 - https://www.cdc.gov/flu/about/disease/us_flu-related_deaths.htm
2 - Institute for Disease Modelling, mentionned by Bill and Melinda Gates Foundation
3 - https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-06/flu-03-ferdinands.pdf
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 961112
Picture
Proudly powered by Weebly
  • COMPANY
    • ABOUT US
    • EXECUTIVE COMMITTEE
    • SCIENTIFIC ADVISORY BOARD
    • CLINICAL ADVISORY BOARD
    • BOARD OF DIRECTORS
    • PARTNERS
  • SCIENCE
  • PIPELINE
    • OVERVIEW
    • INFLUENZA - OVX836
    • CORONAVIRUS
  • NEWS
    • PRESS RELEASES
    • MEDIA COVERAGE
    • PUBLICATIONS
    • EVENTS
  • CONTACT
    • CAREERS >
      • Analyste Business Development
      • Technicien R&D (H/F) Poste en CDD de 6 mois, basé à Lyon (69)
    • LEGAL MENTIONS